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treated with doxycycline (100 mg 2×/d) for 10 days; they 
clinically recovered, and laboratory abnormalities returned 
to reference ranges at discharge 12 days after admission. 
The remaining 22 persons did not report any malaise 
and were examined 1 month after tick bite. They appeared 
healthy at that time, and PCR and ELISA gave negative 
results, arguing against possible asymptomatic B. miya-
motoi infection.
We estimated the probability of B. miyamotoi trans-
mission to humans to be 8.3% (95% CI 4%–18% using a 
Bayesian approach [8] or 95% CI 0%–21% using an SPSS 
bootstrapping procedure [SPSS Inc., Chicago, IL, USA]). 
For comparison, among 68 persons bitten by B. burg-
dorferi sensu lato–infected ticks in the Netherlands, ery-
thema migrans developed in 4.4% (95% C.I. 2.1%–8.3%) 
persons; 3 (4.4%) others seroconverted without clinical 
symptoms (9).
This pilot study has several limitations. We did not 
follow up persons bitten by B. burgdorferi sensu lato– or 
TBEV-infected ticks because they received either antimi-
crobial drugs or anti-TBE immunoglobulin as a preventive 
measure. Because of labor constrains, we did not study per-
sons bitten by “PCR-uninfected” ticks; however, they were 
not hospitalized at RHID, the only hospital in the region 
for patients with evident tick-borne diseases. We did not 
use any serologic techniques specific for relapsing fever 
Borreli (e.g., GlpQ ELISA). Although we did not test for 
Rickettsia or Babesia spp., we did not find TBEV RNA, B. 
burgdorferi sensu lato 16S RNA, pathogenic Ehrlichia 16S 
RNA, or pathogenic Anaplasma DNA in the 2 B. miyamo-
toi–positive patients’ blood samples. 
We demonstrated that the transmission rate of B. mi-
yamotoi appears to be equal to, or higher, than that of B. 
burgdorferi sensu lato (1,9,10). Our data indicate that, an-
nually, clinical B. miyamotoi infection might develop in at 
least 0.005% of persons living in regions to which Ixodes 
spp. ticks and B. miyamotoi are endemic. This estimate cor-
responds to ≈33 cases annually in Izhevsk, which is similar 
to the previously published results of hospital-based sur-
veillance for B. miyamotoi (3,6).
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To the Editor: Zika virus (ZIKV) has been recog-
nized as an emerging mosquito-borne flavivirus since 
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outbreaks were reported from Yap Island in 2007 (1), 
French Polynesia in 2013 (2), and Cook Island and New 
Caledonia in 2014 (3). It has joined dengue virus (DENV) 
and chikungunya virus (CHIKV) as global public health 
threats (4). ZIKV infection typically causes a self-limited 
dengue-like illness characterized by exanthema, low-grade 
fever, conjunctivitis, and arthralgia, and an increase in 
rates of Guillain-Barré syndrome have been observed dur-
ing ZIKV outbreaks (5).
In Brazil, clusters of cases of acute exanthematous 
illness have been reported from various regions since late 
2014, and in April 2015, ZIKV was identified as the eti-
ologic agent (6). In May 2015, the Brazilian Ministry of 
Health recognized circulation of ZIKV in Brazil. We report 
epidemiologic findings for an ongoing outbreak of acute 
exanthematous illness in the population of Salvador, the 
third largest city in Brazil.
The Salvador Epidemiologic Surveillance Office 
(ESO) was first alerted to cases of an acute exanthematous 
illness early in 2015. Reporting of cases increased during 
March, and in April the ESO established 10 public emer-
gency health centers in Salvador as sentinel units for sys-
tematic surveillance of patients with acute exanthematous 
illness of unknown cause. The units searched retrospec-
tively for suspected cases by review of medical charts of 
patients treated since February 15, continued with prospec-
tive case detection, and submitted weekly reports of identi-
fied cases to the ESO.
During February 15-June 25, a total of 14,835 cases 
of an indeterminate acute exanthematous illness were re-
ported from the 12 sanitary districts in Salvador. The over-
all attack rate was 5.5 cases/1,000 persons (4.6 cases/1,000 
men and 6.3 cases/1,000 women, 8.2 cases/1,000 children 
<15 years of age, 5.4 cases/1,000 persons 15–39 years of 
age, and 3.8 cases/1,000 adults >40 years of age).
The epidemic curve peaked in the first week of May, 
which was 1 week after molecular diagnosis of ZIKV in 8 
patients residing ≈50 km from Salvador and during a pe-
riod of intense media coverage of the outbreak (Figure) (6). 
Reporting of suspected dengue cases in Salvador did not 
vary substantially from that in other years and was >5 times 
lower: 2,630 cases, of which 165/366 (45.1%) were posi-
tive for dengue IgM, 20/590 (3.4%) positive for dengue 
virus nonstructural protein 1, and 1/11 (9.1%) positive for 
dengue virus by reverse transcription PCR (Figure). During 
the same period, 58 cases of suspected chikungunya were 
reported and 24 patients with suspected Guillain-Barré syn-
drome were hospitalized.
The median age of case-patients was 26 years (inter-
quartile range 11–39 years), but all age groups were af-
fected, which is a pattern typical of spread of new microor-
ganisms (or subtypes) in a susceptible population. Median 
duration of symptoms at time of medical attention was 1 
day (interquartile range 0–3 days). All patients had exan-
thema and most (12,711/14,093 [90.2%]) had pruritus. Fe-
ver (4,841/13,786, 35.1%), arthralgia (278/1,048 [26.5%]), 
headache (3,446/13,503 [25.6%]), and myalgia (223/1,033 
[21.6%]) were less common.
Serum samples from some patients were examined for 
rubella IgM (2/200, 1.0% positive), rubella IgG (15/18, 
83.3% positive), measles IgM (0/11, 0% positive), den-
gue nonstructural protein 1 (3/185, 1.6% positive), dengue 
IgM (17/80, 21.3% positive), parvovirus B19 IgM (0/1, 0% 
positive), and parvovirus B19 IgG (1/1, 100% positive). 
Reverse transcription PCR was performed on 58 serum 
samples stored at –20°C and confirmed ZIKV in 3 (5.2%) 
samples, CHIKV in 3 (5.2%) samples, DENV type 3 in 1 
(1.7%) sample, and DENV type 4 in 1 (1.7%) sample.
Identification of ZIKV, CHIKV and DENV as etiolog-
ic agents of acute exanthematous illness suggests that these 
3 Aedes spp. mosquito-transmitted viruses were co-circu-
lating in Salvador and highlights the challenge in clinically 
differentiating these infections during outbreaks. Although 
we were not able to determine the specific incidence of 
each virus, the low frequency of fever and arthralgia, which 
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 21, No. 12, December 2015 2275
LETTERS
Figure. Reported cases of indeterminate acute exanthematous 
illness and suspected dengue fever in Salvador, Brazil, by date of 
medical care, February 15−June 25, 2015. Letters indicate specific 
events. A) February 15: systematic reporting of cases of acute 
exanthematous illness of unknown cause begins in Salvador. B) 
April 13: Salvador Epidemiologic Surveillance Office releases its 
first epidemiologic alert about the outbreak in Salvador. C) April 
29: Zika virus is confirmed in 8 samples from patients residing 
≈50 km from Salvador (http://portalsaude.saude.gov.br/index.php/
situacao-epidemiologica-dados-dengue-2) and media coverage of 
the outbreak intensifies (http://www.correio24horas.com.br/detalhe/
noticia/doenca-misteriosa-que-atinge-cidades-baianas-e-identificada-
como-zika-virus/?cHash = 74792c41f3128395ba0ffa5e1ed9dbbe). 
D) May 14: Brazilian Ministry of Health announces circulation of Zika 
virus in Brazil (http://portalsaude.saude.gov.br/index.php/o-ministerio/
principal/secretarias/svs/noticias-svs/17702-confirmacao-do-zika-
virus-no-brasil). E) June 11: Brazilian press announces that cases of 
Zika virus infection have been confirmed in 8 states in Brazil  
(http://www1.folha.uol.com.br/cotidiano/2015/06/1640752-virus-primo-
da-dengue-zika-ja-tem-casos-confirmados-em-oito-estados.shtml).
are indicators of dengue and chikungunya, point to ZIKV 
as the probable cause of several of the reported cases. Fur-
thermore, laboratory-confirmed cases of infection with 
ZIKV were simultaneously identified in other cities within 
metropolitan Salvador (6,7) and in other states in Brazil (8). 
Low diagnosis of ZIKV infection is likely because viremia 
levels among infected patients appear to be low (9).
The spread of ZIKV represents an additional challenge 
for public health systems, particularly because of the risk 
for concurrent transmission of DENV and CHIKV by the 
same vectors, Ae. aegypti and Ae. albopictus mosquitoes, 
which are abundant throughout tropical and subtropical re-
gions. To date, the largest outbreak of chikungunya in Bra-
zil occurred in 2014 in Feira de Santana, Bahia, ≈100 km 
from Salvador, where dengue is also prevalent (10).
This report illustrates the potential for explosive si-
multaneous outbreaks of ZIKV, CHIKV, and DENV in 
the Western Hemisphere and the increasing public health 
effects of Aedes spp. mosquitoes as vectors. The apparent 
increase in reports of Guillain-Barré syndrome during the 
outbreak deserves further investigation to elucidate wheth-
er this syndrome is associated with ZIKV infection. Pub-
lic health authorities in Brazil and neighboring countries 
should plan accordingly.
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To the Editor: In May 2015 an isolate of the recent-
ly emerged variant of rabbit hemorrhagic disease virus 
(RHDV), RHDV2, was identified in an Australian wild rab-
bit (Oryctolagus cuniculus). RHDV2 (also called RHDVb) 
was first described in outbreaks in France in 2010 (1), then 
Italy and Spain in 2011 (2,3) and in Portugal from 2012 
onwards (4). The virus is a genetically and antigenically 
distinct variant of RHDV that is able to partially overcome 
immunity to classical strains of RHDV (1,2). In contrast 
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